Blair William & Co. IL Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Blair William & Co. IL lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,592 shares of the biopharmaceutical company’s stock after selling 486 shares during the period. Blair William & Co. IL’s holdings in Alnylam Pharmaceuticals were worth $3,454,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth approximately $27,000. Bessemer Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares during the last quarter. Ameritas Advisory Services LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $42,000. Washington Trust Advisors Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 53.5% in the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 61 shares during the last quarter. Finally, Larson Financial Group LLC raised its holdings in shares of Alnylam Pharmaceuticals by 77.7% in the first quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 87 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $464.95 on Tuesday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $484.21. The company has a 50 day simple moving average of $452.27 and a two-hundred day simple moving average of $347.50. The stock has a market cap of $60.95 billion, a price-to-earnings ratio of -188.24 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. During the same period in the previous year, the business posted ($0.13) EPS. The business’s revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 8,924 shares of the company’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares of the company’s stock, valued at $24,434,206.60. The trade was a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock worth $44,160,261 in the last 90 days. 1.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Bank of America raised their price target on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Chardan Capital raised their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, August 1st. JPMorgan Chase & Co. decreased their price target on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a report on Monday. Jefferies Financial Group raised their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a report on Monday, July 7th. Finally, BMO Capital Markets lifted their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Twenty-four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $457.08.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.